We are live on ! Find out more

Jazz Pharmaceuticals

JAZZ

Market cap $14B

215.98 USD

+8.15

3.92%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

215.98

0.00

0%

1 day

3.92%

5 days

0.32%

1 month

-6.71%

3 months

-16.41%

6 months

6.38%

Year to date

24.74%

1 year

58.46%

5 years

58.98%

10 years

97.3%

About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Employees: 2,890

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52.4%

Neutral 40.5%

Negative 7.1%

The Motley Fool

Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine

Jazz Pharmaceuticals' financial results are improving. The company's oncology business could push sales and earnings even higher.

Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine

Zacks Investment Research

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the risk of death by 24% versus trastuzumab plus chemotherapy For U.S. media and investors only DUBLIN, Oct. 23, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without Tevimbra® (tislelizumab-jsgr), as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results from the second interim, and final formal, analysis were presented as a late-breaking rapid oral presentation (LBA79) at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

Zacks Investment Research

Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks and earnings pressures.

Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong gross margins (92.1% non-GAAP), and raised FY guidance to $4.60–$4.75B. Ziihera's FDA approval for 1L HER2-positive GEA marks a major oncology expansion, with clinical data showing a significant survival benefit over standard of care.

Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Zacks Investment Research

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

The Motley Fool

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

See News Rankings

Price charts implemented using Lightweight Charts™